Cell & Gene: The Podcast
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson
Nov 21, 2023
Richard Wilson, Senior VP at Astellas, discusses gene therapy deal-making, Astellas' strategic approach post Audentes acquisition, building gene therapy infrastructure, advancements in gene therapy, strategic focus areas like genetic regulation and immuno-oncology, and the importance of partnerships in the cell and gene therapy sector.
25:02
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Astellas aims to develop an end-to-end gene therapy unit focusing on platform, pipeline, and people.
- Gene therapy landscape expects major clinical data releases and global accessibility challenges in the coming months.
Deep dives
Stellis' Aim to Build a World-Class Gene Therapy Infrastructure
Stellis' ambition in gene therapy is to create an end-to-end business unit focused on translating genetic potential into marketed products to benefit patients. The three main areas of focus are platform, pipeline, and people. The company has a strong AAV platform and infrastructure supporting its pipeline growth, including partnerships with other companies like Kate Therapeutics and TASER gene therapies to enhance its offerings.
